BRD2 and neoplasm: A reduction in CA 19-9 plasmatic levels >10% (compared to baseline levels) are deemed a favorable response to NAT, and CA 19-9 response to NAT is a better indicator of the tumor’s biological behavior than its absolute pretreatment values.[8,9,12,20]